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Executive Summary
Worldwide, it is estimated that two million children are infected with HIV (USAID 2005). The vast
majority of these infections are the result of mother-to-child transmission (MTCT) of the virus during
pregnancy, labor, or breastfeeding. However, there are effective methods for prevention of mother-tochild transmission (PMTCT). Botswana is one of the first countries in the developing world with a
national PMTCT program that uses an efficacious and complex regimen to reduce vertical transmission.
At the time of this evaluation (August – December 2005), the standard of care for prevention of MTCT of
HIV in Botswana included three-drug antiretroviral therapy for HIV-infected women with a CD4 count of
< 200; twelve weeks of zidovudine (AZT) for women with CD4>200 (300 mg AZT in the morning and
300 mg AZT in the evening); four weeks of AZT for their infants; single-dose maternal and infant
nevirapine (NVP); and 12 months of free infant formula. Botswana’s PMTCT program also provided
routine HIV testing for all pregnant women during antenatal care (ANC) to identify HIV-positive women
for prophylaxis or treatment.
While programs often report the number of individuals beginning AZT and receiving nevirapine for
PMTCT, effectiveness is dependent on the level of adherence of individuals to these regimens. To
describe adherence of pregnant women to the current PMTCT regimen, the Horizons Program of the
Population Council, in collaboration with the Centers for Disease Control and Prevention (CDC) and
Premiere Personnel in Botswana, conducted an evaluation to describe HIV-related services provided to
women during their pregnancies, document the content of post-test counseling sessions for HIV-positive
pregnant women, whether HIV-positive women remembered what had been discussed, the extent of AZT
adherence based on self-reports, and the operational successes and barriers to adherence to AZT for
PMTCT.

Methods
Francistown, Botswana’s second largest urban area, served as the study location for this evaluation. Data
were collected from August-December 2005 at 10 primary health clinics, one hospital, and during home
visits. In order to evaluate post-test counseling content, providers of PMTCT services (n = 43) were
interviewed and post-test counseling sessions with HIV-positive pregnant women were observed (n = 22).
For evaluation of adherence to AZT for PMTCT, HIV-positive pregnant women at antenatal clinics (n =
122) and HIV-positive women in the postnatal ward (n = 125) were interviewed. Additionally, home
visits were conducted with a subset of women interviewed on the postnatal ward to evaluate adherence to
the four week infant AZT regimen (n = 34).

Key Findings
Provider-initiated routine HIV testing in the antenatal care settings has increased coverage,
and is both feasible and acceptable.
Nearly all HIV-positive pregnant women in this evaluation had tested for HIV during their current
pregnancy and only five women approached for the study were not eligible to participate because they did
not know their HIV status. In contrast, only a third of women with a previous birth had tested during their
1

previous pregnancy, indicating that Botswana’s 2004 opt-out testing policy has increased testing
coverage, enabling health providers to provide PMTCT services to more HIV-positive women. Moreover,
almost all HIV-positive women indicated that they wanted to take the HIV test when they were pregnant,
demonstrating that not only is HIV testing feasible, but it is also acceptable in this setting.

Most HIV-positive pregnant women received one post-test counseling session.
More than two-thirds of all HIV-positive women interviewed in this evaluation had one post-test
counseling session at the ANC clinic. The median time providers reported spending on a post-test
counseling session with HIV-positive women was 28 minutes, with 20 minutes being the most common
response.

Providers had different notions of what information was essential to communicate to HIVpositive pregnant women, and observed counseling sessions revealed incomplete delivery of
important information.
When providers were asked what general information they believed was important in post-test counseling
for HIV-positive women, many combinations of responses were given and only two responses were
mentioned by more than half of the respondents. These were evaluating women for ARV therapy and
using condoms. Also, responses were different when stratified by provider type, with results for nurses
and midwives varying from those given by HIV counselors.
In addition to there being little standardization in provider opinions of essential information, there were
also differences found related to AZT adherence counseling. While over half of those providing
adherence counseling said they discussed the importance of taking the correct dose and taking it on
schedule, far fewer providers reported discussing other important topics, such as the purpose of AZT and
side effects.
The researchers developed a checklist to assess the quality of post-test counseling sessions for HIVpositive pregnant women. The only item on the checklist discussed in all 22 post-test counseling sessions
observed was the meaning of an HIV-positive test result. Almost all of the sessions included the
availability of ARV therapy and the need for a CD4 test to determine when AZT should be started.
However, specific information offered on PMTCT varied greatly and was incomplete in most cases.

Most women recalled that key topics had been discussed during post-test counseling
sessions, but gaps remained.
The majority of women remembered information on why AZT is needed, how to take AZT, and the
importance of taking AZT on schedule. Only 14 percent of participants recalled receiving written
materials developed specifically for HIV-positive women.
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More than eight out of ten HIV-positive women reported starting ARV prophylaxis during
their pregnancy.
Of 118 ANC clinic respondents, 81 percent reported that they started taking AZT for PMTCT. No ANC
clinic respondents were on lifelong ARV therapy. Of 125 postnatal ward respondents, 16 were on lifelong
ARV therapy. Among the remaining 109 respondents, 90 percent reported that they began AZT during
their pregnancy for PMTCT.

Reported adherence to AZT for PMTCT was generally good, but 30-40% of women missed
at least some doses during their pregnancies.
Adherence in this evaluation was measured by self-report. Among ANC clinic respondents who began
AZT for PMTCT, 71 percent took AZT the morning of their interview, 92 percent had taken the
appropriate number of tablets the two days prior to the interview, and 71 percent reported that they had
never missed a dose of AZT. Among postnatal ward respondents, 89 percent reported that they took AZT
the morning and evening of the last day before they went to the hospital and 59 percent reported that they
never missed a dose of AZT during their whole pregnancy.

The majority of women reported that adherence to their AZT regimen was easy.
Eighty-three percent of all respondents found taking AZT to be either very easy or somewhat easy. Only 5
percent found it to be very difficult. Among women who reported missing doses of AZT, being away
from home without medication, running out of pills, and forgetting to take a dose were the most common
reasons given for missing doses.

The majority of respondents refill their AZT when they have little or none left, and women
were given inconsistent supplies of pills.
Women reported being given anywhere from one to four weeks worth of AZT tablets at a time. While the
majority of women found that picking up AZT was convenient, most respondents waited until they had
little to no AZT left before refilling. Running out of pills was the second most often cited reason for
missing doses of AZT.

Infant AZT was provided consistently at the delivery sites, and the vast majority of women
reported adhering to the infant AZT regimen.
All 34 postpartum women interviewed reported that they were sent home from the postnatal
ward with AZT for their infant. These women were interviewed about adherence to the four-week
infant regimen of AZT. All 34 reported administering AZT to the infant at least once during the infants’
first four weeks of life. Two women stopped giving their infant AZT without finishing the four-week
regimen. Among the remaining 32 women, 78 percent reported that they had never missed giving their
infant a dose of AZT. Among the 28 women who were still giving the regimen, 86 percent reported
following the regimen correctly in the four days prior to the interview.
3

Few women were informed about available community resources for support.
Less than a third of all respondents were informed about their eligibility to receive a food basket or about
where to go to meet other HIV-positive women to receive support.

Recommendations
The following recommendations emerged from the study:
•

•
•

•
•
•
•

Standardize post-test counseling content through the use of job aids. The WHO/CDC Testing and
Counseling for PMTCT support tools are designed to provide standardized information and can be
customized by country programs. Adoption of these materials would expedite the introduction of
standardized counseling. The tools are available at (http://www.who.int/hiv/pub/vct/tc/en/index.html).
Adapt existing WHO written materials for distribution to HIV-positive mothers and pilot their
usefulness in Botswana.
Include as part of counseling an assessment of each client’s understanding of essential HIV
information. Before leaving the counselor’s office, clients should understand at least the need to have
their CD4 count checked, the meaning of the CD4 count, and information on PMTCT, including a
specific AZT start date, and be aware that the counselor can provide ongoing support and information
throughout the pregnancy.
Encourage provision of at least two post-test counseling sessions for each woman. The same essential
information should be covered in both sessions, increasing the likelihood of retention of the
information.
Encourage women to bring partners and other family members to visit the counselor with them, to
increase family understanding of HIV and PMTCT and encourage HIV testing for other family
members.
Improve the AZT distribution process by standardizing the time interval for AZT refill pick-up, which
would reduce the frequency of refills, and encourage women to refill their AZT before they run out of
pills.
Government health facilities should improve the distribution of information about community
resources, such as support groups, health services, and nutritional services, and actively help women
to access these services.
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Introduction
Worldwide, two million children are estimated to be living with HIV and 2000 are thought to be newly
infected each day (USAID 2005). These infant infections are primarily a result of mother-to-child
transmission (MTCT) of the virus during pregnancy, labor, or breastfeeding. Clinical trials in Thailand in
1998 and in Uganda in 1999 demonstrated that the risk of vertical transmission of HIV can be reduced by
nearly 50 percent through administering either a short-course of zidovudine (AZT) to the mother in the
last weeks of pregnancy and during labor, or through administering a single dose of nevirapine to the
mother at the onset of labor and to infants within 72 hours of birth (Shaffer et al. 1999; Guay et al. 1999).
Based on these results, UNICEF supported the initiation of pilot PMTCT programs in 11 countries,
including Botswana. PMTCT services include voluntary HIV counseling and testing, improved obstetric
practices, provision of antiretroviral (ARV) prophylaxis, counseling and support for safer infant feeding
practices, and family planning. The evaluation of the UN-supported programs found that it was feasible to
integrate PMTCT services into the ANC/MCH setting in low resource countries (Rutenberg et al. 2003).
In order for PMTCT programs to be effective at both an individual and public health level, HIV-positive
women need to receive ARV prophylaxis and take the drug as it is prescribed. Measuring adherence is
especially important in the face of serious consequences of low adherence to antiretroviral regimens such
as failure to prevent viral replication and an increased likelihood of developing viral resistance (Turner
2002). While PMTCT programs routinely report the number and percentage of women who receive short
course antiretroviral prophylaxis, there is little data on adherence to prophylactic regimens by women. In
a clinical study setting in Lusaka, Zambia, Stringer et al. (2003) found that adherence to single dose
nevirapine, the simplest short course regimen, was not ideal, with 26 percent of women failing to take the
drug as prescribed.
While single-dose nevirapine is the most widely used regimen for PMTCT programs, in major part due to
its simplicity, the WHO guidelines regarding antiretroviral drugs for preventing HIV infection in infants
recommend that a more efficacious combination regimen (e.g. AZT beginning at 28 weeks and single
dose NVP at delivery) should be the standard of treatment (WHO 2006). Within the developing world,
Botswana was one of the first countries to introduce a combination regimen in its national PMTCT
program. It is thus timely to examine the successes and challenges in Botswana of administering a
combination regimen during pregnancy as well as to document levels of adherence to this more
complicated regimen. Data on administration and adherence to this combined prophylactic regimen will
help guide the incorporation of a complex regimen into current country-specific PMTCT programs.

Overview of PMTCT in Botswana
Botswana has been hard hit by the AIDS epidemic. HIV surveillance data collected among pregnant
women in 2003 showed that overall, 37.4 percent of pregnant women were HIV-positive, and in a third of
the districts, more than 40 percent of pregnant women were infected with HIV (NACA 2003). The
government of Botswana is strongly committed to fighting AIDS. In addition to being one of the first
countries in the world to begin a pilot PMTCT project in 1999, the government quickly moved to scale up
these services and became Africa’s first country to have a national PMTCT program, offering services to
all pregnant women at no charge. Services have been available in every public antenatal clinic since 2002.
At the time of this study, Botswana’s PMTCT program provided routine HIV testing and counseling,
5

twelve weeks of AZT for pregnant women (300 mg AZT in the morning and 300 mg AZT in the
evening), four weeks of AZT for infants, single dose nevirapine for mothers and infants, and 12 months of
infant formula. In addition to its advanced PMTCT services, Botswana also had the continent’s first
nationally scaled-up antiretroviral therapy program, with ARV therapy available in at least 32 towns and
villages throughout the country at the time of this evaluation. Pregnant women with CD4 counts under
200 or an AIDS-defining illness qualify to receive ARV therapy through the national ARV program.

Evaluation Objectives
This evaluation provided an opportunity for policymakers and program managers in Botswana to learn
about the quality of post-test counseling and education, and to identify existing problems with ARV
prophylaxis adherence and referral for therapy. It was also an opportunity for individuals who are
implementing PMTCT activities elsewhere to learn lessons from a well-established program. The
objectives of the evaluation were to:
1. Document the content of post-test counseling sessions for HIV-positive pregnant women and the
retention of this information by the women.
2. Describe the extent to which HIV-positive women who are pregnant or on the postnatal ward receive
and adhere to ARV prophylaxis.
3. Describe operational successes and the specific barriers that women face in taking ARV prophylaxis,
including logistical, personal, and health-related factors which may prevent them from starting or
continuing ARV prophylaxis or therapy.
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Methods
Overview
This evaluation was conducted from August to December 2005 in Francistown, Botswana’s second
largest urban area. Data were collected at 9 primary health clinics, one hospital, and during home visits.
The primary health clinic evaluation sites were: Area W, Boikhutso, Botswelelo, Gerald, Kagiso,
Lapologang, Masego, Tatitown, and Tshwaragano. The hospital evaluation site was Nyangabgwe Referral
Hospital (NRH). There was a range of study participants and points of data collection as outlined in Table
1.
Table 1 Data sources
Study participants

Type of data
collection

Number

Location

HIV-positive pregnant women* (29–36 weeks
gestation)

Client interviews

118**

Antenatal
care clinics

HIV-positive women on the postnatal ward

Client interviews

125

Referral
hospital

HIV-positive women with infants on four-week
AZT prophylaxis

Client interviews

36

Home visits

Provider interviews

43

Clinics and
hospital

Observations

22

Antenatal
care clinics

Providers of PMTCT services
HIV-positive pregnant women* during
counseling sessions

*Both HIV-positive and HIV-negative women were interviewed and observed in order to reduce the possibility of
identifying women as HIV-positive through their participation in the study. However, since the purpose of the
evaluation was to explore adherence, the report only presents data for HIV-positive women.
**While 122 interviews were conducted, data from four (3 percent) of these interviews were too incomplete for
inclusion in the analysis; therefore data from 118 of these interviews are presented in the results section.

Ethical Procedures
The evaluation protocol was reviewed and approved by USAID, CDC, the Health Research and
Development Committee (HRDC) in Botswana, and the Population Council’s Institutional Review Board.
Ethical approval for the study was granted by the latter three institutions. Interviewers were trained on the
importance of following ethical guidelines including maintaining confidentiality. Interviewers requested
written informed consent from all women who were eligible for the study and only those who gave
informed consent were interviewed or observed. There was no compensation for participating in the
evaluation. Interviews and observations were conducted in a private space. Participants were not asked
their names, except those who agreed to a home visit. For these subjects, names were recorded on a
separate sheet, which was linked to the questionnaires by evaluation ID numbers and was kept separate
from the questionnaires. Clinic ID numbers were asked of all women on the postnatal ward in order to
7

check their medical records for receipt of AZT and nevirapine at delivery. The study records forms with
the clinic ID numbers were destroyed after hospital records were accessed. Completed questionnaires
were stored in locked cabinets, and only the research team had access to the data.

Eligibility, Recruitment, and Data Collection Procedures
All pregnant women who were at 29–36 weeks of gestation or who had recently delivered and were at the
postnatal ward, who were 18 years or older, and who already knew their HIV status (positive or negative)
were eligible for the study. Only citizens of Botswana were eligible to participate in the evaluation, as
foreign women are not eligible for PMTCT or ARV services. Clinic providers identified women who met
the eligibility criteria and referred them to the interviewers.
For client interviews from antenatal care clinics, interviewers rotated which clinics they were at on a
weekly basis to reduce the possibility of interviewer bias. The interviews took place either while women
were waiting to be seen by providers or after they received services. By approaching HIV-positive and
HIV-negative women, the interviewers did not create the perception that the study was solely about HIVpositive women, thus avoiding possible stigmatization.
The interviews of women at the postnatal ward took place as women were resting after having recently
delivered. Only HIV-positive women were interviewed in the postnatal ward. Women who experienced
complications during delivery that resulted in their being in obvious pain, heavily medicated, or having
had a stillbirth were ineligible for the study. Women who had already been interviewed at the antenatal
care clinic were also not eligible.
Upon completion of the interview in the postnatal ward, interviewers asked women if they would agree to
be visited at home approximately four weeks postpartum so that questions could be asked about infant
AZT and infant care. All HIV-positive women who were interviewed in the postnatal ward (excluding
those who had twins) and lived within a 40km radius of Francistown (a one hour drive) were asked
whether they would be willing to participate in an interview at home.
Among those who were eligible to take part in the evaluation, a small minority of women did not want to
participate (see Table 2).
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Table 2 Refusal rates
Number of Number of
women
women
approached
who
who were
refused
eligible

Refusal
rate

Reasons for refusal

Antenatal care clinic*

263

18

7%

Refused to disclose status, did
not have time, not interested,
did not want to be interviewed,
was going to start taking AZT
same day approached, would
not provide reason

Postnatal ward
(HIV-positive women only)

127

2

2%

Felt ill, unclear reason

*Women’s HIV status was not disclosed at this time so there is no breakdown of refusal rates by HIV-status.
Interviews with HIV-negative women are not included in this report.

The goal of completing 50 home visits could not be reached. As anticipated, it was challenging to carry
out home visits for various reasons, including cultural traditions that discourage outsiders from visiting
homes during the first three months of the infant’s life, and women not wanting to be visited at their
homes in general.
All PMTCT providers at the antenatal clinics and one midwife at the maternity ward at the hospital were
approached for interview.
Providers were briefed about the observations before they took place. A senior interviewer completed the
observations. She introduced the evaluation to the client and obtained the client’s written informed
consent. The sessions were not chosen at random, but were consecutive observations when the senior
interviewer was on site.

Development of Evaluation Instruments and Training of Interviewers
Principal investigators from the Horizons Program and CDC jointly developed the evaluation protocol
and instruments. The following lists the evaluation instruments:
•
•
•
•
•

Provider questionnaire
Observation of post-test counseling session checklist
Client questionnaire for HIV-positive pregnant women at ANC clinics
Client questionnaire for HIV-positive women in the postnatal ward
Home visit questionnaire for HIV-positive women regarding infant AZT

In addition, there was a client questionnaire for HIV-negative women at ANC clinics, but these data are
not included in this report.

9

Premiere Personnel was the in-country organization that took primary responsibility for data collection
and other related field activities. Premiere Personnel translated the questionnaires into Setswana, back
translated them into English, and pre-tested them.
Premiere Personnel recruited six interviewers who completed training specifically in these instruments
prior to beginning data collection. Training was jointly conducted by Premiere Personnel and the
Horizons Program. Interviewers for this evaluation were female university graduates. Many of them had
previous experience conducting interviews.

Data Analysis
This was an evaluation that had small sample sizes and employed convenience sampling. As such most
of the data presented in this paper is descriptive, and document trends or qualitative findings, and are not
necessarily statistically significant. Moreover, only pooled data are analyzed and thus none of the
analyses account for possible differences by site.

Limitations of the Study
This evaluation employed convenience sampling at PMTCT and delivery sites in one city in Botswana,
and therefore the extent to which results can be generalized to the larger population of all pregnant or
recently delivered women in the country is unknown. However, the findings from the evaluation can be
used to provide insights into the quality of counseling received by HIV-positive pregnant women and
their initiation of and adherence to PMTCT medical regimens.
Adherence was measured by self-report in this evaluation. While self-report tends to overestimate
adherence as compared with other adherence measures, it has been shown to correlate well with viral load
levels (Turner 2002). As this was a cross-sectional study, measures of adherence such as pill counts and
MEMS (Medication Event Monitoring System) were not feasible.
Additionally, sample sizes of observations and respondents for some questions were small. It should be
noted that for ease of reading, the results are often reported in percentages, but caution should be used in
interpreting the data based on these percentages because of the small sample sizes.
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Results
Profile of Respondents
Sociodemographic data of clients
The sociodemographic profiles of HIV-positive pregnant women and HIV-positive postnatal ward women
are reported in Table 3. The mean age of respondents was 26.5 years in the antenatal clinics and 28.2
years in the postnatal ward. Almost all of the respondents reported having a partner, but few of the
respondents were married. Approximately half of the women in both locations were employed and the
mean number of meals eaten per day was three.
There were some notable differences between the sociodemographic characteristics of the respondents in
the antenatal clinics compared to those in the postnatal ward. The following are examples of trends.
Postnatal ward women were more likely to be single, to use a shared water source, and to use more wood
and less gas as their fuel for cooking. These differences are likely due to the following reasons. NRH is a
referral hospital, meaning that patients in the postnatal ward are often referred from smaller towns and
rural areas for services that may not be available in these areas. Some of the women interviewed in the
postnatal ward came from communal farming areas, cattle posts, and other rural locations. On the other
hand, most women attend ANC clinics in their own area. Therefore, the women interviewed in the ANC
clinics in Francistown were most likely from Francistown and likely to be better off economically than
women from surrounding rural areas. The second possible reason may be related to the timeframe of data
collection. Interviews of postnatal ward women at the hospital took place after data collection in the ANC
clinics was completed. Consequently, some women who had received care from the Francistown ANC
clinics could not be interviewed as they had already participated in the study while pregnant.
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Table 3 Sociodemographic data of clients interviewed
HIV-positive
women in
ANC clinics
(n = 118)

HIV-positive
women on
postnatal ward
(n = 125)

27

28

Single

37

58

Cohabiting

52

31

Married

9

10

Widowed

1

1

Have partner* (%)

97

94

Completed at least primary education (7 years) (%)

97

94

Employed (%)

50

46

Tap within house

11

13

Standpipe (outside tap for 1 house)

64

50

Standpipe (shared among houses)

25

37

Gas

62

48

Wood

28

47

Mean age (years)
Marital status (%)

Source of water (%)

Type of fuel used for cooking* (%)

Mean number of meals eaten per day (#)

3.0

2.9

Mean number of live births (#)

1.4

3.0

4.9
(at time of interview)

Mean number of times visited ANC during this
pregnancy (#)

7.9
(n = 122)

*The definition of ‘have partner’ in this sample includes both co-habitation and non co-habitation.
**Sources reported by fewer than 10 percent of respondents in both settings are not included.

Profile of providers and their training
Forty-three providers of counseling and testing services were interviewed in order to learn about their
post-test counseling practices and their perceptions of barriers and operational challenges to receipt of
ARVs by clients.
Forty-two of the interviewed providers were from the nine clinics from which HIV-positive antenatal
women were drawn and one provider was interviewed from Nyangabgwe Referral Hospital (NRH) where
postnatal women were interviewed. The profile of these providers can be seen in Table 4.
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Table 4 Profile of providers
Number (%)
(n = 43)
37 (29–43)

Median age in years (IQR)
Current position (multiple answers possible)*
Nurse

22 (51%)

Midwife

19 (44%)

HIV counselor

13 (30%)

Training courses taken in last five years (multiple answers possible)
PMTCT

35 (81%)

HIV counseling

30 (70%)

Family planning

14 (33%)

Median number of ANC clients seen weekly (IQR)

14 (9–50)

IQR: Interquartile Range
*Specific current positions mentioned by only one individual are not included.

Forty-two of the 43 providers reported that they were trained to perform rapid HIV tests and counsel
patients about results. One individual reported only receiving one hour of training, and the responses for
six participants regarding the length of their training were not recorded. Of the remaining respondents, the
median number of days of training cited was 10 (IQR: 10–20). Thirty-seven of the individuals
interviewed (86 percent) felt that their training had prepared them to provide counseling.

Profile of providers observed during post-test counseling sessions
In addition to provider interviews, the study investigated the quality of post-test counseling sessions
through observations of post-test counseling sessions with both HIV-positive and HIV-negative pregnant
women.
It is important to note that the profile of providers who were observed is different from the profile of the
providers who were interviewed. While many provider interviews were conducted with nurses and
midwives, observed post-test counseling sessions were mainly of HIV counselors. Thus, as the data are
not coming from the same individuals, differences cannot be interpreted as differences between what
providers say they are doing versus what is actually being done. The design of this portion of the
evaluation was not intended to capture information from the same individuals but rather to learn through
various methods about adherence counseling.
A total of 50 observations were completed with nine different providers. Forty-four of the observations
were of self-identified HIV counselors and six were of self-identified health care auxiliary. Fifteen
observations were of male providers and 35 were of female providers. Twenty-two of these observations
were of counseling sessions with HIV-positive women. All 22 of these sessions were the first time the
client had received post-test counseling at the antenatal care clinic.
13

HIV Counseling and Testing and Post-test Information about ARV
Prophylaxis and Therapy
HIV counseling and testing at the ANC clinic is the starting point for identifying the HIV status of
pregnant women, and includes information about ARV prophylaxis and therapy. This section explores the
information received and the quality of counseling and testing by HIV-positive pregnant women during
post-test counseling as the backdrop to examining adherence. The data presented are from interviews with
providers, observations of post-test counseling sessions, and self-reports from HIV-positive women who
received at least one post-test counseling session.

Provider interviews
Information providers believe is important to convey during post-test counseling for HIV-positive women
The median time that providers reported spending on a post-test counseling session with an HIV-positive
woman was 28 minutes (IQR 20-40), with 20 minutes as the most common response. Half of the
providers stated that they have the opportunity to provide post-test counseling with an individual during
only one session.
Table 5 shows the results when providers were asked what issues they thought a counselor should address
during post-test counseling for HIV-positive pregnant women. Despite the limited time spent on
individual post-test counseling sessions, providers reported a long and broad list of issues that should be
discussed during these sessions. Major themes mentioned included explaining the meaning of the test
result, encouraging women to accept their status and live positively, suggestions of how the individual
could take care of herself both physically and emotionally, how to prevent vertical transmission, and how
to prevent re-infection.
While the sample size for each group is small, this evaluation indicates differences in the information that
different provider types find important when counseling an HIV-positive pregnant woman.
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Table 5 Issues providers thought a counselor should address during post-test
counseling sessions with HIV-positive pregnant women*┼
Provider type‡
Nurse/midwife
(n = 27)
Number (%)

HIV counselor
(n = 13)
Number (%)

Using condoms

21 (77%)

12 (92%)

Evaluation for ARV therapy

13 (48%)

10 (77%)

Avoid reinfection/sexual behavior change

12 (44%)

3 (23%)

Eating well

11 (41%)

2 (15%)

Positive living

10 (37%)

5 (38%)

Accept status

9 (33%)

4 (31%)

Getting partner tested

9 (33%)

3 (23%)

PMTCT

8 (30%)

9 (69%)

Seeking support

6 (22%)

7 (54%)

Meaning of result

6 (22%)

5 (38%)

Disclosure

6 (22%)

4 (31%)

IPT (TB)

4 (15%)

3 (23%)

Condom negotiation

4 (15%)

1 (8%)

Infant formula feeding

3 (11%)

4 (31%)

*Multiple responses possible
┼
Responses mentioned by less than 10 percent of providers were not included.
‡
One provider was a “health care auxiliary” and one was a social worker. These two are not included here.

Provider discussion of AZT adherence
When providers were specifically asked whether they discuss adherence to AZT with their HIV-positive
pregnant clients, 40 out of 42 (95 percent) said that they did. One of the two providers that responded that
they did not provide adherence counseling said that you should only discuss AZT adherence when the
woman had a very low CD4 count while the other did not counsel on adherence as they did not feel that
they were trained adequately to do so. Over half of those providing adherence counseling discussed the
importance of taking the correct dose of medication and of taking the medication on schedule. However,
as can be seen in Table 6, not only did the responses and combination of responses vary greatly, but they
also varied by provider type.
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Table 6 Issues related to AZT adherence that providers thought should be addressed in
counseling sessions with HIV-positive women*
Provider type‡
Nurse/Midwife
(n = 27)
Number

HIV counselor
(n = 13)
Number

17

4

2

7

11

1

Importance/purpose of AZT

9

2

Side effects

4

1

Infant regimen

3

1

Dosing/schedule
Timeframe of prophylaxis
Not missing or skipping doses/not
stopping once started

*Multiple responses possible; responses that were mentioned by less than 10 percent of providers were not included.
‡
One provider was a “health care auxiliary” and one was a social worker. These two are not included here.

Observed counseling sessions with post-test HIV-positive pregnant women
Although the sample size was small, these 22 observations of post-test counseling sessions of HIVpositive pregnant women provide insights regarding the interaction between the counselor and the client,
and what kind of information is being provided and discussed. The median length of time for the
observed sessions was 15 minutes (IQR 10–20).

General information
In all of the post-test counseling sessions, providers explained the meaning of a positive HIV test result.
However, only half of the sessions included an assessment of whether the client understood the meaning
of what was explained. In the vast majority of sessions, providers discussed issues pertaining to a
partner’s HIV status, and most discussed positive living and disclosure of results (see Table 7).
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Table 7 Issues discussed in post-test counseling sessions for HIV-positive pregnant
women (observations)
n = 22
Number
Provider explained meaning of an HIV-positive test result

22

Provider asked if client’s partner/husband has taken an HIV test

20

Provider asked if client knows partner/husband’s HIV status

20

Provider engaged client in discussion about positive living

16

Provider discussed client disclosure of HIV results

16

Provider gave client opportunity to express how she feels about result

15

Provider discussed importance of condoms

14

Provider assessed client’s understanding of an HIV-positive result

11

ARV and PMTCT-specific information
The study also explored what specific information was conveyed with respect to prevention of vertical
transmission, how to be evaluated for ARV therapy, and next steps regarding starting ARV prophylaxis
(see Tables 8 and 9).
In almost all of the sessions, providers discussed the availability of both lifelong ARV therapy and
prophylactic therapy. The majority also explained the need for a CD4 test to determine whether to begin
lifelong therapy or prophylactic therapy.
Table 8 Discussion of ARV therapy in post-test counseling of HIV-positive pregnant
women (observations)
n = 22
Number
Provider informed client about availability of ARV therapy

20

Provider explained that not all pregnant women need ARV therapy immediately,
and that a CD4 test is needed to make this determination

19

Provider created a specific plan (including where and when) for the client to have
her CD4 count checked

20

Providers were less likely to fully explain the details of PMTCT or provide information about specific
next steps for medical and counseling needs.
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Table 9 Discussion of PMTCT in post-test counseling of HIV-positive pregnant women
(observations)
n = 22
Number
Provider explained the following about PMTCT
Mothers take AZT daily from 28 weeks to delivery

18

Another tablet is required during labor

12

Infants take medicine for their first 4 weeks to prevent HIV

15

Most babies will be HIV-negative if the medicines are taken

5

There is still a risk of the baby being HIV-positive

5
12

Provider told client exact date she needs to start AZT
Provider gave client a handout explaining what she needs to do next for
herself and her baby’s health

9

Provider informed client that further counseling is available in the future

9

Interviews with HIV-positive pregnant women in ANC clinics and the postnatal ward
HIV counseling and testing coverage
Nearly all HIV-positive women had an HIV test during their current pregnancy (see Table 10). Among
those who had a previous birth, a third had tested before this pregnancy. This is a broad reflection of how
the change from opt-in to opt-out testing has led to significantly greater rates of HIV testing during
pregnancy. 1
Table 10 Timing of HIV testing
HIV-positive
pregnant
women

HIV-positive
postnatal ward
women

Had HIV test during this pregnancy

95% (n = 118)

87% (n = 125)

Had HIV test before this pregnancy
(among women who had a previous birth)

33% (n = 83)

34% (n = 98)

To ascertain if women felt pressured or coerced within the context of routine provider-initiated HIV
testing, women interviewed in the postnatal ward were asked if they wanted to take an HIV test when

1
To participate in this evaluation, women needed to know their HIV status. The fact that only five women approached by the
researchers were not eligible to participate because they were of unknown status supports high HIV testing rates in the study
facilities.
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they were pregnant. Ninety-four percent of postnatal women stated that they wanted to take an HIV test
when they were pregnant.
Respondents were asked if a counselor at the ANC clinic had talked to them about their HIV test results.
One hundred and nine of the 118 antenatal clinic respondents (92 percent) and 116 of the 124 postnatal
ward respondents (94 percent) were counseled at the ANC clinic about their HIV test result.
Of those that reported meeting with a counselor at the ANC clinic to talk about HIV testing, more than
two-thirds of HIV-positive women reported just one post-test counseling session with the counselor at the
ANC clinic (see Table 11).
Table 11 Number of sessions with counselor at ANC clinic
HIV-positive
pregnant women
(n = 109)
Number (%)

HIV-positive postnatal
ward women
(n = 116)
Number (%)

1

74 (68%)

81 (70%)

2

21 (19%)

16 (14%)

3 or more

14 (13%)

19 (16%)

The analysis discussed throughout the remainder of this section is restricted to the 109 HIV-positive
pregnant women and 116 HIV-positive postnatal ward women who answered affirmatively that a
counselor at the ANC clinic talked to them about HIV testing.

General information HIV-positive clients reported receiving during counseling sessions
For women who indicated that a counselor talked to them about testing, the interviewer asked, “What
things do you remember the counselor saying?” Multiple answers were permitted, and interviewers
probed respondents to recall as much as they could, but they did not mention any specific responses. The
only topic that more than 50 percent of the women remembered being mentioned was PMTCT (Table 12).
Ten percent of antenatal clinic respondents and 11 percent of postnatal ward respondents said that they
remembered nothing that the counselor had discussed with them.
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Table 12 Issues HIV-positive women remember counselors discussing during post-test
counseling*
Antenatal clinic
respondents
(n = 109)
Number (%)

Postnatal ward
respondents
(n = 116)
Number (%)

PMTCT

65 (60%)

59 (51%)

Condom use

33 (30%)

48 (41%)

Infant formula feeding

34 (31%)

35 (30%)

How to be evaluated for ARV therapy

24 (22%)

20 (17%)

Remembered nothing

11 (10%)

13 (11%)

*Responses given by fewer than 10 percent of women in both settings are not included.

In addition to gaps in receipt of information, only a small number of HIV-positive women said they
received a written handout that was developed for them with information about next steps for taking care
of their own health and their infant’s health. Only 32 (14 percent) HIV-positive pregnant and postnatal
ward participants recalled receiving this resource material. Of these women, 23 (72 percent) reported that
they read the information it contained. For those that did read the material, recollection of the information
was poor. While the handout included a wide range of information such as partner testing, ARV
evaluation, and AZT start date, only half mentioned “AZT for PMTCT,” and other recollection of the
handout’s content was negligible.
While general recall of the topics discussed during post-HIV test counseling was low, when women were
asked about discussion of specific issues, recall improved. For example, discussion of both condom use
and disclosure were addressed specifically later in the questionnaire. While only 33/109 (30 percent) of
antenatal respondents and 48/116 (41 percent) of postnatal ward respondents spontaneously mentioned
condom use being discussed in post-test counseling, when asked specifically if the counselor had
discussed condom use with them, the percentage of respondents indicating that this was discussed
increased to 96 and 95 percent, respectively. For disclosure, less than 10 percent of respondents in each
location spontaneously recalled that this had been discussed, but over 50 percent of respondents in each
setting indicated that it had been discussed when specifically asked.
Women tended to remember more when they had received more than one post-test counseling session as
compared to those women who received only one session. For example, 25/35 (71 percent) of women in
antenatal clinics with more than one counseling session remembered having a discussion about PMTCT
versus 40/74 (54 percent) women who had only one session. Among postnatal ward women this
difference was 22/35 (63 percent) versus 37/81 (46 percent) women. Also, of the 25 women in both
settings who said they remembered nothing, 24 had only one visit with the counselor.
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PMTCT-specific information women received during counseling sessions
Among the HIV-positive pregnant respondents, 110/118 (93 percent) indicated that an individual at the
ANC clinic talked to them about ARVs for PMTCT. Ninety-two out of 110 (84 percent) women stated
that a nurse/midwife spoke to them about it, while only 27/110 (25 percent) women mentioned a
counselor. Less than half (47/110; 43 percent) of these women had questions about taking ARVs for
PMTCT, and all of these women indicated that their questions had been answered by someone at the
antenatal care clinic. Among the 110 respondents who talked to someone about ARVs for PMTCT, 75
(68 percent) were able to recall the name AZT (or a derivative of this) as the name of the tablets they
were told to take for PMTCT, while the rest could not remember the name of the tablets.
Both HIV-positive pregnant and postpartum women who had started taking AZT were asked about
specific information they received prior to starting the regimen. While most women reported receiving
information about why AZT is needed, how to take the medication, and the importance of taking AZT on
schedule, only a minority of women learned about possible side effects and how to manage them (see
Table 13).
Table 13 Information HIV-positive women received about AZT among those who started
taking AZT
HIV-positive
pregnant women
(n = 96)
Number (%)

HIV-positive postnatal
ward women
(n = 98)
Number (%)

Why AZT is needed

76 (79%)

85 (87%)

How to take AZT

81 (84%)

90 (92%)

Importance of taking AZT on schedule

71 (74%)

69 (70%)

Side effects

32 (33%)

31 (32%)

What to do if you are having side effects

29 (30%)

20 (20%)

Disclosure
It is important to address disclosure within the context of PMTCT services, as adherence to the program
recommendations is likely to be easier for women who have partners that are aware of and supportive of
their status and need for prophylactic medications.
Data collected in interviews of providers and clients and data collected from observed counseling sessions
are quite different with respect to disclosure during client-provider interactions. Only 10/42 providers (24
percent) interviewed mentioned disclosure when asked what they felt was important to address during
post-test counseling of HIV-positive women. However, 16/22 (73 percent) of observed counseling
sessions of HIV-positive women involved a discussion on disclosure. When asked specifically if a
counselor had discussed disclosure with them, 64/116 (55 percent) of postnatal ward women and 63/109
(56 percent) of antenatal clinic respondents said this had been discussed.
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Despite the uneven counseling on disclosure, there are high rates of disclosure among HIV-positive
women. Of those women who received counseling, 96/109 (88 percent) of the ANC clinic respondents
and 94/116 (81 percent) of postnatal respondents had disclosed their status to someone. Partner/husband
was mentioned most often when asked to whom they had disclosed their status (see Figure 1).
Figure 1 To whom women disclosed their HIV status (among women who disclosed;
multiple answers possible)
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Partner testing
While all of the women interviewed in this evaluation had taken an HIV test, and many had disclosed
their status to their partners/husbands, less than half of the women reported that their partners/husbands
had taken an HIV test (see Table 14).
Table 14 Has your partner/husband taken an HIV test?
HIV-positive
pregnant women
(n = 109)
Number (%)

HIV-positive postnatal
ward women
(n = 116)
Number (%)

Yes

52 (48%)

48 (41%)

No

50 (46%)

45 (39%)

Don’t know

4 (4%)

16 (14%)

N/A because no partner/husband

3 (3%)

7 (6%)
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Providers’ views on improving post-test counseling
When providers were asked if they had ideas of how post-test counseling might be improved, the main
themes in the answers included the need for more staff, more training, and more adequate private space in
which to conduct counseling. When asked what support and resources would help the providers with HIV
counseling and testing, manpower, training, and space were major concerns. The need for materials with
which to educate clients on condom use and HIV prevention was also mentioned.

Receipt of AZT for Prophylaxis and Adherence to Regimen
While PMTCT programs routinely report the number and percentage of women who receive short course
antiretroviral prophylaxis, there is currently little data on the adherence of pregnant women to these
prophylactic regimens. This section explores AZT regimen initiation and adherence data collected from
interviews with HIV-positive women in antenatal clinics and postnatal wards.
Among respondents, receipt of counseling services and then initiation of AZT was relatively high (see
Figure 2).
Figure 2 Overview of services received and initiated by respondents
Antenatal clinic
respondents
(n = 118)

Postnatal ward
respondents
(n = 125)

Received post-test
counseling:
109 (92%)

Received post-test
counseling:
116 (93%)

Were taking AZT
for PMTCT:
96 (81%)

Took AZT
for PMTCT:
98 (78%)

Not on AZT, but
should have been:
22 (19%)

Did not take AZT,
but should have:
11 (9%)

On lifelong ARV:
none

On lifelong ARV:
16 (13%)
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Receipt and initiation of ARV prophylaxis
Antenatal clinic respondents
Table 15 displays data on the initiation of prophylactic AZT by women testing positive for HIV at
antenatal clinics. Of the 118 HIV-positive pregnant respondents, 96 (81 percent) reported AZT initiation.
The recommended time to begin prophylactic AZT during this evaluation was between 28 and 31 weeks
gestation. Of the 93 women that initiated AZT and had complete records, 67 (72 percent) began AZT
within this time frame. The range of initiation (n = 93) was from 21 weeks to 34 weeks gestation.
Table 15 Initiation of ARV prophylaxis in current pregnancy among women in ANC
clinics*
HIV-positive
pregnant women
Mean gestational age at time of interview (n = 117)

32 weeks

Pharmacy records show AZT was started (n = 118)

93 (79%)

Self-report that AZT was started (n = 118)

96 (81%)

Self-report that AZT was started between 28–31 weeks gestation (n = 93)

67 (72%)

Days of AZT use at time of interview (median, IQR) (n = 95)

23 (14–42)

*Note: Sample sizes for individual questions vary because of skip patterns and missing responses.

Postnatal ward respondents
Of the 125 women interviewed in the postnatal ward, 16 (13%) were on therapeutic ARVs and therefore
not included in this section on PMTCT adherence. Of the 109 not on therapeutic ARVs, 98 (90%) had
taken at least one dose of AZT during their pregnancy. Fifty-six percent of women (53/94) began AZT
between 28 and 31 weeks gestation, with starting times ranging from 20 to 39 weeks gestation (see Table
16).
Table 16 Self-reported receipt of ARV prophylaxis among postnatal ward respondents
HIV-positive postnatal
ward women
At least one dose of AZT was taken during pregnancy (n = 109)*

98 (90%)

AZT was started between 28 and 31 weeks gestation (n = 94)

53 (56%)

Days of AZT use during pregnancy (median, IQR) (n = 96)

66 (46–79)

*Note: Sample sizes for individual questions vary because of skip patterns and missing responses.
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Self-reports of AZT and nevirapine during labor were provided only by women who took AZT for
PMTCT (n = 98). Additionally, hospital records were checked for all postnatal ward women that agreed
to have their records checked (n = 122). For maternal AZT and nevirapine, as well as for infant
nevirapine, the hospital records indicated that a greater percentage of women received the proper
medications compared to self-reports. The differences between self-report and hospital records is due to
women not knowing if they or their infant had received these medications and missing responses.
Table 17 Comparison of self-reports and hospital records of receipt of ARV prophylaxis
during labor and infant dose
Self-report:
HIV-positive postnatal
ward women
(n = 98)
Number (%)

Hospital record:
HIV-positive postnatal
ward women
(n = 122)
Number (%)

Mother received AZT during labor

72 (73%)

99 (81%)

Mother received nevirapine during labor

43 (44%)

103 (84%)

Infant received nevirapine syrup after delivery

66 (67%)

121 (99%)

Self-reported maternal adherence to AZT regimen
While self-reports indicate that a large percentage of women in this study initiated ARV prophylaxis for
PMTCT, it is important that women also adhere to medication regimens as prescribed in order for these
preventive measures to be effective. Several questions were included in the study to assess self-reported
adherence to prophylactic AZT.

Antenatal clinic respondents
Self-reported adherence to the AZT regimen among antenatal respondents is shown in Table 18. Eightfive percent of women reported complete adherence to the appropriate medication schedule in the four
days preceding the interview (300 mg AZT in the morning and 300 mg AZT in the evening). Seventy-one
percent of the women also reported that they took AZT the morning of their interview, and 92 percent
said that they had taken the appropriate number of tablets in the two days prior to the interview. Seventyone percent (67/95) of respondents reported that they had never missed a dose of AZT during their current
pregnancy.
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Table 18 Self-reported adherence to AZT regimen: antenatal respondents
Antenatal clinic
respondents
Number (%)
Adherence to appropriate medication schedule during 4 days prior to interview
(n = 94)
Never

3 (3%)

Some or most of the time

11 (12%)

All of the time

80 (85%)

Took AZT the morning of the interview (n = 96)

68 (71%)

Took appropriate number of tablets the two days prior to interview (n = 95)

87 (92%)

Never yet missed a dose during this pregnancy prior to interview (n = 95)

67 (71%)

*Note: Sample sizes for individual questions vary due to missing responses.

Postnatal ward respondents
Among interviewed postnatal ward women, 84 percent reported complete adherence to the appropriate
medication schedule during their last four days of pregnancy. Eighty-nine percent of respondents reported
that they took AZT in the morning and evening on the last day before coming to the hospital. Sixty-four
percent of the women said that they had not missed a dose of AZT in the last 30 days of pregnancy, and
59 percent reported that they had not missed a dose during their whole pregnancy (see Table 19).
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Table 19 Self-reported adherence to AZT regimen: postnatal respondents
Postnatal ward
respondents
(n = 98)
Number (%)
Adherence to appropriate medication schedule during last 4 days of pregnancy
Never

6 (6%)

Some or most of the time

10 (10%)

All of the time

82 (84%)

Took AZT in morning and evening of the last day before coming to the hospital

87 (89%)

Number of times missed a dose during the last 30 days of pregnancy
Never

62 (63%)

1–5

25 (26%)

>5

11 (11%)

Number of times missed a dose during the whole pregnancy
Never

58 (59%)

1–5

23 (23%)

>5

17 (17%)

Adherence to infant’s AZT regimen: Self-reports by home interview respondents
Thirty-six of the women interviewed concerning their AZT prophylaxis practices in the postnatal ward
were visited in their homes four weeks later and participated in interviews to assess their level of
adherence to the recommended four week course of AZT for their infant. While this is a small sample, it
provides insight on the level of adherence to infant AZT.
All women interviewed reported that they were sent home from the postnatal ward with AZT for their
infant and that they had administered at least one dose of AZT to their infant in the first four weeks of
life. At the time of the interview, most women were still giving AZT to their infant, as the questionnaire
was designed to be administered near the end of the four-week period. The majority of the mothers
interviewed also reported that they had never missed giving their child a dose of AZT (see Table 20).
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Table 20 Self-report of adherence to infant’s AZT regimen
Home visit
respondents
(n = 34)*
Number (%)
Hospital staff sent mother home with AZT for infant

34 (100%)

Administered AZT to infant at least once during first 4 weeks of life

34 (100%)

Current administration of AZT
Still giving AZT to infant

28 (82%)

Finished AZT four-week regimen

4 (12%)

Stopped before completing four-week regimen

2 (6%)

How closely was AZT regimen followed in four previous days?
(Of those that were still giving AZT, n = 28)
Some or most of the time

4 (14%)

All of the time

24 (86%)

Number of doses of AZT missed in infant’s life
(Of those who had finished the medication or were still giving it, n = 32)
None

25 (78%)

1–5

7 (22%)

*While 36 women were interviewed, two infants had died prior to the interview.

Reported barriers to ARV initiation or adherence
Of 118 antenatal clinic respondents, 22 (19 percent) had not started taking AZT for PMTCT at the time
they were interviewed. These respondents answered questions about why they had not yet begun taking
AZT. The most common responses were that they were starting the day of the interview, that they were
waiting for more information before starting, or that they had registered late. Eight of these 22
respondents (36 percent) did not know they were supposed to begin taking the tablets.
Of 109 women interviewed in the postnatal ward that should have taken AZT for PMTCT, 11 (10
percent) responded that they had not done so. Among the 10 women for whom information is available,
six stated that someone at the antenatal care clinic did talk to them about short course prophylaxis. The
reasons for not starting AZT given by women in the postnatal ward included not having the time or
money to go to the clinic, not knowing who to ask for help, not taking an HIV test, and not taking
medication because they were not symptomatic.
The small number of women not initiating AZT short course prophylaxis for PMTCT indicates that
women are willing to take ARVs in order to protect their infants from acquiring HIV at birth. However,
once on prophylactic ARVs, it is important to understand some of the barriers that women face adhering
to the medical regimen. Table 21 indicates that the majority of respondents in both settings found taking
AZT as prescribed to be easy, with very few responding that it was “very difficult” to take AZT.
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Table 21 How respondents find taking AZT
Antenatal clinic
respondents
(n = 95)
Number (%)

Postnatal clinic
respondents
(n = 98)
Number (%)

Very easy

58 (61%)

66 (67%)

Somewhat easy

18 (19%)

19 (20%)

Somewhat difficult

14 (15%)

8 (8%)

5 (5%)

5 (5%)

Taking AZT is…

Very difficult

In order to understand personal barriers to women’s adherence to AZT, women were asked how many
times they had missed a dose of AZT. Twenty-eight women in the antenatal clinics and 40 women in the
postnatal ward reported that they had missed at least one dose. The most common reasons reported for
missing a dose included being away from home without their medication, running out of pills, forgetting
to take pills, and being busy with other things (see Table 22). Of these, running out of pills suggests the
need, from an operational standpoint, to change the frequency with which women are told to return to
pick up additional pills.
Table 22 Most common reasons for missing doses of AZT among women who reported
missing at least one dose*
Antenatal clinic
respondents
(n = 28)
Number (%)

Postnatal clinic
respondents
(n = 40)
Number (%)

Was away from home without medication

15 (54%)

18 (45%)

Ran out of pills

13 (46%)

18 (45%)

Simply forgot to take pills

13 (46%)

11 (28%)

Was busy with other things

7 (25%)

7 (18%)

Fell asleep or slept through dose time

2 (7%)

6 (15%)

Had problem taking at correct time

3 (11%)

5 (13%)

Was trying to avoid side effects

4 (14%)

2 (5%)

Felt too depressed or overwhelmed

3 (11%)

4 (10%)

Did not have time to visit clinic

3 (11%)

4 (10%)

Did not have food to take medicine with

3 (11%)

3 (8%)

*Responses that were reported by under 10 percent of women in both settings are excluded from the above table.
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For infant adherence, the sample size was small and only seven out of thirty two women (whose infants
had finished the medication or were still giving it) said that they had ever missed a dose of AZT for their
infant. Reasons for missing doses among these seven women included not understanding how to give the
AZT, being away from home, being busy, forgetting, and sleeping through the dose.

Operational Successes and Barriers
Operational issues associated with clients obtaining ARVs for PMTCT
The majority of women found it necessary to pick up AZT once every week or once every two weeks.
This is frequent, but most respondents indicated that this frequency and pharmacy hours were convenient.
The majority of women did not have to travel more than two kilometers to pick up their medication and
were able to travel this distance by walking or public transportation. Once they were at the clinic, almost
all respondents felts that the clinic staff protected their privacy. A few women reported that the pharmacy
had run out of AZT when it was needed.
As reported in the section on personal barriers to medication adherence, running out of pills was the
second most common reason for missing a dose of AZT. This is likely due to the fact that almost all
women were refilling their AZT often, and half of women did not pick up their refills until they had no
remaining medication. Table 23 highlights operational issues associated with obtaining ARVs for
PMTCT.
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Table 23 Operational factors involved in women accessing AZT for prophylaxis
HIV-positive
pregnant women
(n = 95)a
Number (%)

HIV-positive postnatal
ward women
(n = 98)a
Number (%)

Once a week

24 (25%)

48 (49%)

Once every two weeks

53 (56%)

30 (31%)

6 (6%)

7 (7%)

12 (13%)

13 (13%)

Picking up AZT is convenient

87 (93%)

94 (96%)

Pharmacy hours are convenient

84 (88%)

96 (98%)

9 (9%)

19 (19%)

91 (97%)

90 (92%)

< 1 km

52 (55%)

55 (56%)

1–2 km

25 (26%)

20 (20%)

3–4 km

9 (9%)

7 (7%)

> 4km

9 (9%)

16 (17%)

66 (69%)

69 (70%)

7 (7%)

8 (8%)

24 (25%)

20 (21%)

14 (15%)

4 (4%)

None was left

48 (51%)

57 (58%)

One to few days left

43 (45%)

36 (37%)

Week’s supply left

2 (2%)

1 (1%)

Only picked up once

1 (1%)

4 (4%)

How often AZT picked up:

Once a month
Other

*

Pharmacy has been out of AZT when it was needed
Clinic staff protected privacy
Distance traveled to obtain AZT

Mode of transport used to pick up AZT
Walking
Car
Public transportation
Received extra AZT in case they could not return to
clinic in time
AZT was refilled when…

a

Not all groups of answers add to 100% as some were missing 1–2 responses.
*“Other” included answers without timeframes, such as “during ANC visits” or “when finished.”
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Provider-perceived barriers to clients accessing ARV prophylaxis
Follow-up with clients is an important part of any treatment regimen. When specifically asked if they
talked to women about PMTCT medications or gave PMTCT medications, all providers responded that
they did. All also said that women were educated on how and when to take the medication by nurses,
midwives, or counselors. However, only 18 of the 43 respondents (42 percent) said that they followed up
with patients to make sure that they took the correct dose at the correct time. Half of those who did not
follow up with women cited lack of time and/or manpower as the primary reason. Other reasons included
that it is not their duty to follow up, that the women are too difficult to locate for follow-up, and that they
trust that the women are adhering properly.
Only six of the providers acknowledged that there had been difficulties in administering AZT. Of these
six, three said that the difficulties were caused by using 100 mg tablets instead of having access to 300 mg
tablets. 2 The other three noted that women do not take their AZT properly, they register too late, and that
some women refuse to know their HIV status until after they deliver.

Community Resources
It is important for HIV-positive women to be aware of community resources and support services that can
help them cope with their HIV status. During the interviews, HIV-positive women were asked questions
about access to and awareness of community resources. Most women did not receive information from
clinic staff about their eligibility to receive a food basket or where to go to meet other HIV-positive
women (see Table 24).
Table 24 Knowledge of community resources among HIV-positive women
HIV-positive
pregnant women
(n = 118)
Number (%)

HIV-positive postnatal
ward women
(n = 125)
Number (%)

Learned from someone at the ANC clinic that they are
eligible to receive a food basket

32 (27%)

26 (21%)

Learned from someone at the ANC clinic where to go
to meet other HIV-positive women to receive support

13 (11%)

27 (22%)

Knows where to go to meet other HIV-positive women

19 (16%)

36 (29%)

Clinics and hospitals were the most commonly mentioned sources of information and services, suggesting
that there are not many community resources that these women are aware of.

2

Women take 300 mg of AZT two times daily. Use of 100 mg tablets causes staff to count out three times more tablets than if
they used 300 mg tablets.
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Discussion and Recommendations
This evaluation was designed as an opportunity for policymakers and program managers in Botswana to
learn about the quality of HIV post-test counseling, education of HIV-positive pregnant women, and any
existing problems with ARV prophylaxis adherence. The findings can be used to help design and test
activities to improve the quality of counseling that HIV-positive pregnant women receive, to increase the
number of women starting ARV prophylaxis or therapy, and to improve adherence to these medications.
For stakeholders in other resource-constrained settings, this evaluation demonstrates the feasibility of
administering a more complex regimen within ANC/MCH. While different challenges may arise
depending on contextual factors, the lessons learned from Botswana can be applied to other settings.

HIV Counseling and Testing
Testing acceptance was high in this study, and represents a large improvement over findings from a study
based on the Botswana AIDS Impact Survey in 2001 (Rakgoasi 2005). While coverage of testing was
very high in this sample, the quality of information transmission to HIV-infected women could be
improved.
As HIV counseling is a woman’s first point of contact with the health system in learning how to cope
with her HIV status, receiving a positive result is an emotional experience. This can be compounded when
a woman is pregnant and faced with the possibility of passing the virus on to her child. In this study more
than two-thirds of women received only one post-test counseling session. Therefore it is particularly
important that this session be structured and standardized in order to effectively transmit essential
information as well as provide emotional support.
When providers were asked what general information they believed was important to convey to HIVpositive women during post-test counseling, there were many different combinations of responses. In
addition, only two responses were mentioned by more than half of the respondents; this suggests that
providers have very different notions of what is considered essential information. There was also large
variation in opinions of what women need to hear regarding AZT adherence. These findings suggest that
there are no standardized post-test counseling materials being followed by providers for covering predetermined key information.
Observations of post-test counseling sessions with HIV-positive pregnant women revealed that in most
cases the information delivered in these sessions was incomplete. Of all of the information on the posttest counseling check list used to evaluate these sessions, explaining the meaning of an HIV positive test
result was the only item discussed in all 22 observations. Nearly all of these 22 observations did include
the mention of availability of ARV therapy and initial information about CD4 testing. However, there
were severe gaps in the information provided on PMTCT. Moreover, in less than half of observed
sessions, providers distributed the handout that explained next steps for safeguarding the health of women
and infants, and in a similar proportion of sessions, mentioned that the client could receive further
counseling in the future.
Results from studies in South Africa and Kenya also point to the need for standardization of counseling as
these countries aim to improve and scale up PMTCT services in an effective manner (Chopra et al. 2005;
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Delva et al. 2006). Delva et al. (2006) point out that, as in our evaluation where the majority of counselors
spend only 20–30 minutes on post-test counseling with HIV-positive women, “the limited time dedicated
to women receiving antenatal VCT contrasts with the heavy and comprehensive load of health
information and advice they are supposed to receive.” These studies as well as ours suggest that there are
key gaps in the delivery of information to HIV-positive pregnant women. In this evaluation we were able
to examine the views of providers stratified by occupational title. Although the sample size was small,
nurses and midwives differed from HIV counselors (possibly due to differences in their training,
knowledge base, and experience) in terms of what they deemed to be important to discuss. This indicates
the need to standardize training across all providers conducting post-test counseling. As Botswana’s
health system includes dedicated HIV counselors, it would be helpful to have clearly delineated roles
explaining what information counselors are responsible for relaying to clients and what information
nurses/midwives should be responsible for relaying.
During the time of this evaluation, there were no standardized tools. The impact of the lack of
standardized counseling is reflected in the poor recall of important topics discussed during post-test
counseling sessions among the women interviewed in this study. The wide range in topics remembered,
the fact that only one topic was mentioned by more than 50 percent of women interviewed in both the
antenatal clinics and the postnatal ward, and the fact that 10 percent of women in both groups did not
remember anything that was discussed demonstrates a severe gap in the flow of knowledge to these
women and their ability to retain information. For future studies, it will be important to assess women’s
retention of knowledge as an important indicator of the effectiveness of counseling. While not statistically
significant, results from this study suggest that women who have more than one counseling session
tended to recall more than women who received only one session, indicating that women may benefit
from receiving more than one counseling session.
Standardization of counseling and role delineation is especially important in the face of routine opt-out
HIV testing in the antenatal clinic setting. Since 2004, the national PMTCT program in Botswana has
implemented provider-initiated routine HIV testing. This has led to significant increases in the percentage
of women who know their HIV status at delivery and the percentage of women receiving PMTCT
interventions, indicating that routine testing has been well accepted (Creek et al. 2007). As uptake of
PMTCT interventions increase, there must be concurrent evaluation of the quality of services received to
ensure that the interventions are effective.
Kiarie et al. (2003) found that to improve compliance with PMTCT regimens there was a need for greater
involvement of partners. It is encouraging that in this study, among women who disclosed,
partner/husband was the most frequently mentioned individual, with more than 80 percent of HIVpositive women reporting having disclosed to their partner/husband. This suggests that Botswana’s
national leadership, public health interventions, and media campaigns have worked to fight the HIV
epidemic not only through increased prevention, treatment, and care services, but also through decreasing
the fear and stigmatization that are often responsible for a lack of disclosure. HIV serostatus disclosure
initiates discussion among sexual partners that can lead to behavior change, a discussion of
contraceptives, and increased partner support for accessing PMTCT and other treatment and care
programs (Medley et al. 2004). The importance of disclosure in the prevention of vertical transmission of
HIV makes it a priority topic for inclusion in any standardized counseling materials.
Less than half of the women in this study reported that their partner had tested. The discrepancy in the
level of testing between these women and their partners may in part be attributed to routine testing of
women offered during antenatal care, while men do not have a comparable opportunity where they are
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encouraged to test. This supports the need to implement WHO’s recommendation that HIV counseling
and testing be a part of diagnostic assessments and clinical evaluations when individuals present to health
care facilities (WHO/UNAIDS 2007). In addition to providing men opportunities for counseling and
testing during other diagnostic assessments, the ability to conduct couples testing and counseling in the
context of antenatal care could also be explored in order to facilitate disclosure and support between
partners (Semrau et al. 2005; Painter 2001).

AZT Receipt and Adherence
The majority of women did take AZT for PMTCT or were on therapeutic ARVs during their pregnancy.
Receipt of maternal AZT and maternal and infant nevirapine at delivery was also high. While it is
encouraging that the vast majority of women delivering at the hospital were receiving the medications
they and their infant need based on hospital records, it is important to note that many of the women were
unaware that they or their infant had received these medications. This indicates the need for increasing
awareness of these medications and their purpose among HIV-positive women.
Women’s self-reports demonstrated that the majority of mothers and infants were adhering to their
respective AZT regimen, but there is room for improvement, as optimal adherence to antiretroviral
regimens should be greater than 95 percent (Paterson et al. 2000) This study identified a number of
factors that may negatively impact adherence, such as one-off counseling that does not provide essential
information, lack of follow-up once women start their AZT regimen, and the need for women to collect
medication frequently. While most women lived close to a pharmacy and said that this was convenient,
running out of pills was a main reason for missing doses of AZT. This suggests that many missed doses
may be averted if a two-week supply was standard and if women were encouraged to refill their AZT
before it ran out. Additionally, expanded counseling and follow-up of HIV-positive women should be
considered as measures PMTCT services can take to foster adherence to ARVs.
While the sample size for infant adherence is small, the fact that only two mothers stopped administering
AZT and that most reported high levels of adherence to the schedule indicates that mothers are both
willing and able to adhere to a four-week AZT regimen for their infants.
As this study relied on self-reports for assessing adherence by women and infants, prospective evaluations
that are able to observe adherence through multiple methods are needed.

Community Resources
Support from health workers, family members, partners, and the community can be important in order to
attain the levels of participation and adherence needed to substantially decrease the burden of mother-tochild transmission of HIV. Currently, referral of HIV-positive pregnant women to community resources is
poor. This needs to be improved in order to ensure the health and well-being of HIV-positive women and
their families.
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Recommendations
The following recommendations emerged from the study:
•

•
•

•

•
•
•

Standardize post-test counseling content through the use of job aids. The WHO/CDC Testing and
Counseling for PMTCT support tools are designed to provide standardized information and can be
customized by country programs. Adoption of these materials would expedite the introduction of
standardized counseling. The tools are available at (http://www.who.int/hiv/pub/vct/tc/en/index.html).
Adapt existing WHO written materials for distribution to HIV-positive mothers and pilot their
usefulness in Botswana.
Include as part of counseling an assessment of each client’s understanding of essential HIV
information. Before leaving the counselor’s office, clients should understand at least the need to have
their CD4 count checked, the meaning of the CD4 count, and information on PMTCT, including a
specific AZT start date, and be aware that the counselor can provide ongoing support and information
throughout the pregnancy.
Encourage provision of at least two sessions with the counselor for each woman. The second session
may be able to focus more on PMTCT program reinforcement, support, and adherence, whereas the
first may focus more on accepting and understanding the HIV-positive test. To a great extent, though,
the same essential information should be covered in both sessions, increasing the likelihood of
retention of the information.
Encourage women to bring partners and other family members to visit the counselor with them, to
increase family understanding of HIV and PMTCT and encourage HIV testing for other family
members. .
Improve the AZT distribution process by standardizing the time interval for AZT refill pick-up, which
would reduce the frequency of refills, and encourage women to refill their AZT before they run out of
pills.
Government health facilities should improve the distribution of information about community
resources, such as support groups, health services, and nutritional services, and actively help women
to access these services.
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